The U.S. Food and Drug Administration has cracked down on the predatory marketing of breast binders to gender-confused girls, issuing stern warning letters to 12 manufacturers and retailers for illegally promoting these devices as tools for treating gender dysphoria and achieving a masculine appearance. FDA Commissioner Dr. Marty Makary, in a powerful press conference, denounced the “transgender-medical-industrial complex” for exploiting vulnerable youth, declaring this action a vital step to halt the barbaric push of radical gender ideology on children.
Makary emphasized that breast binders, classified as Class I medical devices, have legitimate uses like aiding women post-breast cancer surgery, but long-term wear poses severe risks including chronic pain, impaired lung function, and breastfeeding difficulties. He lambasted the ideology as “predatory” and “wrong,” noting how it’s foisted upon kids by rogue teachers and pediatricians without parental consent, leading to irreversible harms like drugs, castration, and mastectomies.
A targeted warning to California-based GenderBender LLC highlighted their website’s endorsement of chest binding for “gender euphoria” in the LGBT community, revealing how profit-driven companies fuel this moral crisis.The FDA demands immediate corrective measures from violators, threatening seizures and injunctions for non-compliance, signaling a long-overdue regulatory rebuke to the transgender lobby’s assault on innocence.